secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001628280-22-027967
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma Q3 net loss $21.6M; Phase 3 WHIM data on track for Q4; CMO departure, CCO appointed
--------------------------------------------------------------------------------

- Net loss of $21.6M for Q3 2022, vs $20.2M in Q3 2021; cash $81.1M as of Sept 30, 2022, sufficient into Q3 2023.
- R&D expenses $14.1M, SG&A $6.0M; PIPE financing gross proceeds $55M in July 2022.
- Phase 3 4WHIM trial top-line data anticipated Q4 2022; NDA submission early H2 2023 if positive.
- Positive Phase 1b data for mavorixafor in chronic neutropenia; trial expanding to Phase 1b/2 in H1 2023.
- Mark Baldry appointed CCO; CMO Diego Cadavid to resign by end of 2022, Dr. Murray Stewart interim CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828022027967/0001628280-22-027967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828022027967/xfor-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer